Phathom Pharmaceuticals is focusing on gastroenterologists to increase adoption of its drug VOQUEZNA, aiming for sustainable profitability. The company reported an 88% revenue increase to $74.3 million in Q2 2026, with reduced selling expenses and expects full-year revenue between $310 million and $325 million, maintaining an 80% gross margin. Supported by $182.5 million in cash and improved cash flows, Phathom faces risks from revenue-interest financing and competition from tegoprazan. Key growth drivers include rising covered prescriptions, disciplined spending, and development of as-needed dosing.
Remittix has raised $33 million and will burn 300 million RTX tokens, reducing supply by 20% ahead of public trading starting November 24, 2026. This token burn and near-cap funding boost scarcity and investor interest. Meanwhile, the XRP Ledger's No...
XTransfer, a leading global B2B cross-border payment platform, made its first appearance at Money20/20 USA 2026 in Las Vegas to accelerate its expansion into Latin American markets. The company recently completed regulatory registration in Chile, ena...
Kelvin Veras Real Estate completed 16 real estate transactions in its first year operating in New Jersey, including sales, purchases, rentals, and landlord services. This milestone highlights the company's successful market entry and diverse client s...
The documentary 'NURSE: Empathy Heals' premiered on October 21 in Nashville, showcasing personal stories of nurses and the critical role of empathy in healthcare. It highlights the emotional challenges nurses face, especially during crises like the C...
Oxford Square Capital Corp. announced it will hold a conference call on October 30, 2026, at 9:00 AM Eastern time to discuss its third quarter 2026 earnings. Investors can join the call via a toll-free number, and a recorded replay will be available ...
